
ZBH Stock Forecast & Price Target
ZBH Analyst Ratings
Bulls say
Zimmer Biomet Holdings has demonstrated a robust turnaround, evidenced by an 11.3% growth in its BoneCement and Surgical segments due to successful placements of the Rosa technology. The firm benefits from a healthy balance sheet and has consistently shown growth in line or above its peers across multiple quarters, supported by the favorable orthopedic market conditions. Additionally, the company’s knee segment exhibited a global growth rate of 5.3%, driven by innovative product offerings and increasing market penetration, which positions it well for future profitability.
Bears say
Zimmer Biomet Holdings (ZBH) faces a challenging outlook due to stagnant average selling prices (ASP) anticipated for FY25 and lowered growth estimates across revenue segments, projecting only 5.4% year-over-year growth for FY26. The company's knee and hip product lines have demonstrated weaker performance relative to peers, with significant market share risks coupled with execution challenges hindering growth. Additionally, potential delays in the commercialization of new products like ROSA and increased restructuring costs further contribute to a cautious assessment of ZBH's financial trajectory.
This aggregate rating is based on analysts' research of Zimmer Biomet Hlds and is not a guaranteed prediction by Public.com or investment advice.
ZBH Analyst Forecast & Price Prediction
Start investing in ZBH
Order type
Buy in
Order amount
Est. shares
0 shares